<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/latestarticles/journal?journal=bmcblooddisord&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Blood Disorders - Latest Articles</title>
        <link>http://www.biomedcentral.com/bmcblooddisord/</link>
        <description>The latest research articles published by BMC Blood Disorders</description>
        <dc:date>2009-07-07T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2326/9/4" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2326/9/3" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2326/9/2" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2326/9/1" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2326/8/2" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2326/8/1" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2326/7/1" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2326/6/7" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2326/6/6" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2326/6/5" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1471-2326/9/4">
        <title>Application of tri-colour, dual fusion fluorescence in situ hybridization (FISH) system for the characterization of BCR-ABL1 fusion in chronic myelogenous leukaemia (CML) and residual disease monitoring</title>
        <description>Background:
We studied the application of the BCR-ABL1 + 9q34 tri-colour dual fusion fluorescence in situ hybridization (FISH) system in the characterization of fusion signal pattern and the monitoring of residual disease in chronic myelogenous leukaemia (CML). The signal constellation on metaphases with the tri-colour dual fusion system was defined. The knowledge of various signal patterns obtained from the different genetic rearrangements was further applied to the analysis of hybridization signals on interphase nuclei.
Methods:
BCR-ABL1 dual colour, dual fusion FISH (D-FISH) was performed on diagnostic samples of 22 CML patients. The tri-colour FISH system was performed on cases that showed aberrant signal patterns other than the classical 1 green (G) 1 orange (O) 2 fusions (F). Using the aqua band-pass filter, random signal overlap in interphase nuclei would be indicated by the presence of an aqua signal (ASS1), while genuine fusion was represented by the absence of the ASS1 signal.
Results:
Using the D-FISH system, the signal patterns could be categorized into 4 groups: group 1 (n = 17) showed the classical 1G1O2F; group 2 (n = 2) showed 2G1O1F indicating ABL1 deletion; group 3 (n = 1) showed 1G2O1F indicating BCR deletion; group 4 (n = 2) with 1G1O1F indicating reciprocal ABL1-BCR deletion. The tri-colour dual fusion system correlated with the D-FISH system for cases with der(9) deletion. The added aqua-labelled ASS1 probe was useful in differentiating random signal overlap from genuine BCR-ABL1 fusion in the interphase cells (group 4).
Conclusion:
Although the D-FISH probe was valuable in establishing the different patterns of aberrant signals and monitoring patients with the classic 2-fusion signals in CML, the tri-colour dual fusion probe should be used for patients with der(9) deletion to monitor response to treatment.</description>
        <link>http://www.biomedcentral.com/1471-2326/9/4</link>
                <dc:creator>Lisa Siu</dc:creator>
                <dc:creator>Edmond Ma</dc:creator>
                <dc:creator>Wai-shan Wong</dc:creator>
                <dc:creator>Man-hong Chan</dc:creator>
                <dc:creator>Kit-fai Wong</dc:creator>
                <dc:source>BMC Blood Disorders 2009, 9:4</dc:source>
        <dc:date>2009-07-07T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2326-9-4</dc:identifier>
        <prism:publicationName>BMC Blood Disorders</prism:publicationName>
        <prism:issn>1471-2326</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2009-07-07T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2326/9/3">
        <title>Prevalence, phenotype and inheritance of 
benign neutropenia in Arabs
</title>
        <description>Background:
Benign neutropenia, i.e., neutropenia not associated with an increased risk of infection, may result in serious medical consequences when a &apos;standard&apos; definition of neutropenia (absolute neutrophil count (ANC) &lt; 1.5 &#215; 109cells/L) is universally applied to all races. The aims of this study were to determine the prevalence of benign neutropenia among healthy Arabs and evaluate its mode of inheritance.
Methods:
ANCs were studied prospectively amongst a healthy indigenous population (n = 1032) from the United Arab Emirates undergoing a nation-wide sickle-cell and thalassemia screening program. The mean neutrophil count and the prevalence of benign neutropenia were compared by age, sex and amongst various tribes.
Results:
The mean neutrophil count (&#215; 109cells/L) was 3.3 (range 0.95&#8211;7.6). Benign neutropenia was present in 110 (10.7%) subjects of whom 24 (2.3%) individuals had moderate neutropenia (ANC 0.5 &#8211; 1.0 &#215; 109 cells/L). In the 22 tribe-family groups, the prevalence of benign neutropenia varied between 0% and 38%. Benign neutropenia showed no difference in the frequency amongst the sexes (p = 0.23) and it was independent of age (Spearman&apos;s rho = 0.05, p = 0.13). The age-related mean neutrophil count was the lowest in Arabs when compared with other ethnic groups (Blacks, Europeans and Mexicans). The inheritance of benign neutropenia was consistent with an autosomal dominant pattern; however, the diversity of observed phenotypes suggested the presence of more than one genetic variant for this trait.
Conclusion:
Arabs have a high prevalence of benign neutropenia that may be inherited as an autosomal dominant trait.</description>
        <link>http://www.biomedcentral.com/1471-2326/9/3</link>
                <dc:creator>Srdjan Denic</dc:creator>
                <dc:creator>Saad Showqi</dc:creator>
                <dc:creator>Christoph Klein</dc:creator>
                <dc:creator>Mohamed Takala</dc:creator>
                <dc:creator>Nicolas Nagelkerke</dc:creator>
                <dc:creator>Mukesh Agarwal</dc:creator>
                <dc:source>BMC Blood Disorders 2009, 9:3</dc:source>
        <dc:date>2009-03-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2326-9-3</dc:identifier>
        <prism:publicationName>BMC Blood Disorders</prism:publicationName>
        <prism:issn>1471-2326</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2009-03-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2326/9/2">
        <title>Factors associated with hospital readmission in sickle cell disease</title>
        <description>Background:
Sickle cell disease is the most frequent hereditary disease in Brazil, and people with the disease may be hospitalised several times in the course of their lives. The purpose of this study was to estimate the hazard ratios of factors associated with the time between hospital admissions.
Methods:
The study sample comprised all patients admitted, from 2000 to 2004, to a university hospital in Rio de Janeiro State, south-east Brazil, as a result of acute complications from sickle cell disease (SCD). Considering the statistical problem of studying individuals with multiple events over time, the following extensions of Cox&apos;s proportional hazard ratio model were compared: the independent increment marginal model (Andersen-Gill) and the random effects model.
Results:
The study considered 71 patients, who were admitted 223 times for acute events related to SCD. The hazard ratios for hospital readmission were statistically significant for the prior occurrence of vaso-occlusive crisis and development of renal failure. However, analysis of residuals of the marginal model revealed evidence of non-proportionality for some covariates.
Conclusion:
the results from applying the two models were generally similar, indicating that the findings are not highly sensitive to different approaches. The better fit by the frailty model suggests that there are unmeasured individual factors with impact on hospital readmission.</description>
        <link>http://www.biomedcentral.com/1471-2326/9/2</link>
                <dc:creator>Monique Loureiro</dc:creator>
                <dc:creator>Suely Rozenfeld</dc:creator>
                <dc:creator>Marilia Carvalho</dc:creator>
                <dc:creator>Rodrigo Portugal</dc:creator>
                <dc:source>BMC Blood Disorders 2009, 9:2</dc:source>
        <dc:date>2009-02-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2326-9-2</dc:identifier>
        <prism:publicationName>BMC Blood Disorders</prism:publicationName>
        <prism:issn>1471-2326</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2009-02-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2326/9/1">
        <title>FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia</title>
        <description>Background:
Primary eosinophlia associated with the FIP1L1-PDGFRA rearrangement represents a subset of chronic eosinophilic leukaemia (CEL) and affected patients are very sensitive to imatinib treatment. This study was undertaken in order to examine the prevalence and the associated clinicopathologic and genetic features of FIP1L1-PDGFRA rearrangement in a cohort of 15 adult patients presenting with profound eosinophilia (&gt; 1.5 &#215; 109/L).
Methods:
Reverse transcriptase-polymerase chain reaction (RT-PCR) was used for the detection of FIP1L1-PDGFRA rearrangement and the results confirmed by direct sequencing. C-KIT-D816V mutation was analysed retrospectively by PCR and restriction-fragment-length-polymorphism (PCR-RFLP), in all cases with primary eosinophilia.
Results:
Two male patients with splenomegaly carried the FIP1L1-PDGFRA rearrangement, whilst 2 others were ultimately classified as suffering from idiopathic hypereosinophlic syndrome (HES) and one from systemic mastocytosis. These patients were negative for the C-KIT-D816V mutation and received imatinib (100&#8211;400 mg daily). Patients with CEL and HES responded to imatinib and remained in complete haematological, clinical and molecular (for carriers of FIP1L1-PDGFRA rearrangement) remission for a median of 28.2 months (range: 11&#8211;54), whilst the patient with systemic mastocytosis did not respond. Interestingly, in both patients with FIP1L1-PDGFRA rearrangement, the breakpoints into PDGFRA were located within exon 12 and fused with exons 8 and 8a of FIP1L1, respectively.
Conclusion:
An early diagnosis of FIPIL1-PDGFRA-positive CEL and imatinib treatment offer to the affected patients an excellent clinical therapeutic result, avoiding undesirable morbidity. Moreover, although the molecular mechanisms underlying disease pathogenesis remain to be determined, imatinib can be effective in patients with idiopathic HES.</description>
        <link>http://www.biomedcentral.com/1471-2326/9/1</link>
                <dc:creator>Gedeon Loules</dc:creator>
                <dc:creator>Fani Kalala</dc:creator>
                <dc:creator>Nikolaos Giannakoulas</dc:creator>
                <dc:creator>Emmanouil Papadakis</dc:creator>
                <dc:creator>Panagiota Matsouka</dc:creator>
                <dc:creator>Matthaios Speletas</dc:creator>
                <dc:source>BMC Blood Disorders 2009, 9:1</dc:source>
        <dc:date>2009-02-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2326-9-1</dc:identifier>
        <prism:publicationName>BMC Blood Disorders</prism:publicationName>
        <prism:issn>1471-2326</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2009-02-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2326/8/2">
        <title>Estimation of transient increases in bleeding risk associated with physical activity in children with haemophilia</title>
        <description>Background:
Although it is widely appreciated that vigorous physical activity can increase the risk of bleeding episodes in children with haemophilia, the magnitude of the increase in risk is not known. Accurate risk estimates could inform decisions made by children with haemophilia and their parents about participation in physical activity and aid the development of optimal prophylactic schedules. The aim of this study is to provide an accurate estimate of the risks of bleeding associated with vigorous physical activity in children with haemophilia.Methods/DesignThe study will be a case-crossover study nested within a prospective cohort study. Children with moderate or severe haemophilia A or B, recruited from two paediatric haematology departments in Australia, will participate in the study. The child, or the child&apos;s parent or guardian, will report bleeding episodes experienced over a 12-month period. Following a bleeding episode, the participant will be interviewed by telephone about exposures to physical activity in the case period (8 hours before the bleed) and 2 control periods (an 8 hour period at the same time on the day preceding the bleed and an 8 hour period two days preceding the bleed). Conditional logistic regression will be used to estimate the risk of participating in vigorous physical activity from measures of exposure to physical activity in the case and control periods.DiscussionThis case-control study will provide estimates of the risk of participation in vigorous physical activity in children with haemophilia.</description>
        <link>http://www.biomedcentral.com/1471-2326/8/2</link>
                <dc:creator>Carolyn Broderick</dc:creator>
                <dc:creator>Robert Herbert</dc:creator>
                <dc:creator>Jane Latimer</dc:creator>
                <dc:creator>Chris Barnes</dc:creator>
                <dc:creator>Julie Curtin</dc:creator>
                <dc:creator>Paul Monagle</dc:creator>
                <dc:source>BMC Blood Disorders 2008, 8:2</dc:source>
        <dc:date>2008-06-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2326-8-2</dc:identifier>
        <prism:publicationName>BMC Blood Disorders</prism:publicationName>
        <prism:issn>1471-2326</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2008-06-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2326/8/1">
        <title>Safety of intramuscular influenza vaccine in patients receiving oral anticoagulation therapy: a single blinded multi-centre randomized controlled clinical trial</title>
        <description>Background:
Influenza vaccines are recommended for administration by the intramuscular route. However, many physicians use the subcutaneous route for patients receiving an oral anticoagulant because this route is thought to induce fewer hemorrhagic side effects. Our aim is to assess the safety of intramuscular administration of influenza vaccine in patients on oral anticoagulation therapy.
Methods:
Design: Randomised, controlled, single blinded, multi-centre clinical trial. Setting: 4 primary care practices in Barcelona, Spain. Participants: 229 patients on oral anticoagulation therapy eligible for influenza vaccine during the 2003&#8211;2004 season. Interventions: intramuscular administration of influenza vaccine in the experimental group (129 patients) compared to subcutaneous administration in the control group (100 patients). Primary outcome: change in the circumference of the arm at the site of injection at 24 hours. Secondary outcomes: appearance of local reactions and pain at 24 hours and at 10 days; change in INR (International Normalized Ratio) at 24 hours and at 10 days. Analysis was by intention to treat using the 95% confidence intervals of the proportions or mean differences.
Results:
Baseline variables in the two groups were similar. No major side effects or major haemorrhage during the follow-up period were reported. No significant differences were observed in the primary outcome between the two groups. The appearance of local adverse reactions was more frequent in the subcutaneous administration group (37,4% vs. 17,4%, 95% confidence interval of the difference 8,2% to 31,8%).
Conclusion:
This study shows that the intramuscular administration route of influenza vaccine in patients on anticoagulant therapy does not have more side effects than the subcutaneous administration route.Registration numberNCT00137579 at clinicaltrials.gov</description>
        <link>http://www.biomedcentral.com/1471-2326/8/1</link>
                <dc:creator>Josep Casajuana</dc:creator>
                <dc:creator>Begona Iglesias</dc:creator>
                <dc:creator>Mireia Fabregas</dc:creator>
                <dc:creator>Francesc Fina</dc:creator>
                <dc:creator>Joan-Antoni Valles</dc:creator>
                <dc:creator>Rosa Aragones</dc:creator>
                <dc:creator>Mencia Benitez</dc:creator>
                <dc:creator>Edurne Zabaleta</dc:creator>
                <dc:source>BMC Blood Disorders 2008, 8:1</dc:source>
        <dc:date>2008-05-29T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2326-8-1</dc:identifier>
        <prism:publicationName>BMC Blood Disorders</prism:publicationName>
        <prism:issn>1471-2326</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2008-05-29T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2326/7/1">
        <title>Impact of delayed initiation of erythropoietin
in critically ill patients</title>
        <description>Background:
The purpose of this study was to evaluate the impact of recombinant human erythropoietin (rHuEPO) use for anemia of critical illness at a practice site where delayed initiation is common.
Methods:
Retrospective medical record review involving patients treated with rHuEPO for anemia of critical illness. Those patients given rHuEPO or diagnosed with end-stage renal disease (ESRD) prior to ICU admission were excluded. The primary endpoints were rHuEPO use and RBC transfusion patterns.
Results:
Complete data were collected for consecutive admissions of 126 patients. Average age (SD) and APACHE II score were 56.5 (18.6) years and 25 (7.8), respectively. The median ICU (IQR) and hospital length of stay (LOS) were 24 (11.25, 39) and 29 (17, 44.75) days, respectively. Treatment with rHuEPO was started an average of 12.5 +/- 10.5 days after ICU admission and given for 3.8 +/- 3.8 doses. Eighty percent of patients were transfused with an average total of 5.42 +/- 5.08 units received. RBC exposure inversely correlated with a lower mean hemoglobin response to rHuEPO. ICU LOS (p &lt; 0.0001), hemoglobin at 24 hours (p = 0.055), transfusion within 48 hours of admit (p &lt; 0.0001), and postoperative status (p = 0.019) were the best predictors of transfusion requirements (r2 = 0.37).
Conclusion:
Delayed initiation of rHuEPO for anemia of critical illness resulted in comparable hemoglobin and transfusion benefits. Future studies are needed to establish clinical benefit and role in therapy. RBC exposure may blunt the erythropoietic effects of rHuEPO, potentially frustrating benefits to those of greatest apparent need.</description>
        <link>http://www.biomedcentral.com/1471-2326/7/1</link>
                <dc:creator>Jeremiah Duby</dc:creator>
                <dc:creator>Brian Erstad</dc:creator>
                <dc:creator>Jacob Abarca</dc:creator>
                <dc:creator>James Camano</dc:creator>
                <dc:creator>Yvonne Huckleberry</dc:creator>
                <dc:creator>Stuart Bramblett</dc:creator>
                <dc:source>BMC Blood Disorders 2007, 7:1</dc:source>
        <dc:date>2007-10-04T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2326-7-1</dc:identifier>
        <prism:publicationName>BMC Blood Disorders</prism:publicationName>
        <prism:issn>1471-2326</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2007-10-04T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2326/6/7">
        <title>Spontaneous intra-peritoneal bleeding secondary to warfarin, presenting as an acute appendicitis: a case report and review of literature</title>
        <description>Background:
Warfarin is a coumarin anti-coagulant, used widely for the therapeutic and prophylactic anticoagulation. Although, it is considered as a life saving medicine, it is associated with the significant adverse effects including intra-abdominal bleeding, which have been very well documented in literature. However, the presentation of warfarin induced intra-peritoneal bleeding as an acute appendicitis has not been reported in English literature. We report this rare, spontaneous intra-peritoneal bleeding secondary to warfarin therapy, mimicking the signs and symptoms of an acute appendicitis for the first time in English literature.Case presentationA 41 year-old female patient who was on warfarin for prophylaxis following the previous episode of pulmonary embolism, presented to the Casualty with the typical symptoms of an acute appendicitis. During operative intervention, we found it to be the spontaneous intra-peritoneal bleeding secondary to warfarin. The patient recovered well following the operation.
Conclusion:
We recommend the use of the radiological investigations in all the cases of acute abdomen who are on warfarin even if the INR is within the therapeutic range.</description>
        <link>http://www.biomedcentral.com/1471-2326/6/7</link>
                <dc:creator>Jayesh Sagar</dc:creator>
                <dc:creator>Vikas Kumar</dc:creator>
                <dc:creator>Dharmendra Shah</dc:creator>
                <dc:creator>Ashok Bhatnagar</dc:creator>
                <dc:source>BMC Blood Disorders 2006, 6:7</dc:source>
        <dc:date>2006-10-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2326-6-7</dc:identifier>
        <prism:publicationName>BMC Blood Disorders</prism:publicationName>
        <prism:issn>1471-2326</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2006-10-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2326/6/6">
        <title>Genetic background determines response to hemostasis and thrombosis</title>
        <description>Background:
Thrombosis is the fatal and disabling consequence of cardiovascular diseases, the leading cause of mortality and morbidity in Western countries. Two inbred mouse strains, C57BL/6J and A/J, have marked differences in susceptibility to obesity, atherosclerosis, and vessel remodeling. However, it is unclear how these diverse genetic backgrounds influence pathways known to regulate thrombosis and hemostasis. The objective of this study was to evaluate thrombosis and hemostasis in these two inbred strains and determine the phenotypic response of A/J chromosomes in the C57BL/6J background.
Methods:
A/J and C57Bl/6J mice were evaluated for differences in thrombosis and hemostasis. A thrombus was induced in the carotid artery by application of the exposed carotid to ferric chloride and blood flow measured until the vessel occluded. Bleeding and rebleeding times, as surrogate markers for thrombosis and hemostasis, were determined after clipping the tail and placing in warm saline. Twenty-one chromosome substitution strains, A/J chromosomes in a C57BL/6J background, were screened for response to the tail bleeding assay.
Results:
Thrombus occlusion time was markedly decreased in the A/J mice compared to C57BL/6J mice. Tail bleeding time was similar in the two strains, but rebleeding time was markedly increased in the A/J mice compared to C57BL/6J mice. Coagulation times and tail morphology were similar, but tail collagen content was higher in A/J than C57BL/6J mice. Three chromosome substitution strains, B6-Chr5A/J, B6-Chr11A/J, and B6-Chr17A/J, were identified with increased rebleeding time, a phenotype similar to A/J mice. Mice heterosomic for chromosomes 5 or 17 had rebleeding times similar to C57BL/6J mice, but when these two chromosome substitution strains, B6-Chr5A/J and B6-Chr17A/J, were crossed, the A/J phenotype was restored in these doubly heterosomic progeny.
Conclusion:
These results indicate that susceptibility to arterial thrombosis and haemostasis is remarkably different in C57BL/and A/J mice. Three A/J chromosome substitution strains were identified that expressed a phenotype similar to A/J for rebleeding, the C57Bl/6J background could modify the A/J phenotype, and the combination of two A/J QTL could restore the phenotype. The diverse genetic backgrounds and differences in response to vascular injury induced thrombosis and the tail bleeding assay, suggest the potential for identifying novel genetic determinants of thrombotic risk.</description>
        <link>http://www.biomedcentral.com/1471-2326/6/6</link>
                <dc:creator>Jane Hoover-Plow</dc:creator>
                <dc:creator>Aleksey Shchurin</dc:creator>
                <dc:creator>Erika Hart</dc:creator>
                <dc:creator>Jingfeng Sha</dc:creator>
                <dc:creator>Jonathan Singer</dc:creator>
                <dc:creator>Annie Hill</dc:creator>
                <dc:creator>Joseph Nadeau</dc:creator>
                <dc:source>BMC Blood Disorders 2006, 6:6</dc:source>
        <dc:date>2006-10-05T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2326-6-6</dc:identifier>
        <prism:publicationName>BMC Blood Disorders</prism:publicationName>
        <prism:issn>1471-2326</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2006-10-05T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2326/6/5">
        <title>Birth characteristics and the risk of childhood leukaemias and lymphomas in New Zealand: a case-control study</title>
        <description>Background:
Some studies have found that lower parity and higher or lower social class (depending on the study) are associated with increased risks of childhood acute lymphoblastic leukaemia (ALL). Such findings have led to suggestions that infection could play a role in the causation of this disease. An earlier New Zealand study found a protective effect of parental marriage on the risk of childhood ALL, and studies elsewhere have reported increased risks in relation to older parental ages. This study aimed to assess whether lower parity, lower social class, unmarried status and older parental ages increase the risk of childhood ALL (primarily). These variables were also assessed in relation to the risks of childhood acute non-lymphoblastic leukaemia, non-Hodgkin&apos;s lymphomas and Hodgkin&apos;s disease.
Methods:
A case control study was conducted. The cases were 585 children diagnosed with leukaemias or lymphomas throughout New Zealand over a 12 year period. The 585 age and sex matched controls were selected at random from birth records. Birth records from cases (via cancer registration record linkage) and from controls provided accurate data on maternal parity, social class derived from paternal occupation, maternal marital status, ages of both parents, and urban status based on the address on the birth certificate. Analysis was by conditional logistic regression.
Results:
There were no statistically significant associations overall between childhood ALL and parity of the mother, social class, unmarried maternal status, increasing parental ages (continuous analysis), or urban status. We also found no statistically significant associations between the risks of childhood acute non-lymphoblastic leukaemia, non-Hodgkin lymphomas, or Hodgkin&apos;s disease and the variables studied.
Conclusion:
This study showed no positive results though of reasonable size, and its record linkage design minimised bias. Descriptive studies (eg of time trends of ALL) show that environmental factors must be important for some diagnoses. Work has been done on the risk of ALL in relation to chemicals (eg pesticides) and drugs, dietary factors (eg vitamins), electromagnetic fields and infectious hypotheses (to name some); but whether these or other unknown factors are truly important remains to be seen.</description>
        <link>http://www.biomedcentral.com/1471-2326/6/5</link>
                <dc:creator>Donny Wong</dc:creator>
                <dc:creator>John Dockerty</dc:creator>
                <dc:source>BMC Blood Disorders 2006, 6:5</dc:source>
        <dc:date>2006-09-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2326-6-5</dc:identifier>
        <prism:publicationName>BMC Blood Disorders</prism:publicationName>
        <prism:issn>1471-2326</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2006-09-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
